BioXcel Therapeutics (BTAI) Total Debt (2018 - 2026)

BioXcel Therapeutics' Total Debt history runs 9 years deep, the most recent figure standing at $100.3 million for Q1 2026.

• On a quarterly basis, Total Debt fell 4.96% year-over-year to $100.3 million in Q1 2026; TTM through Mar 2026 was $100.3 million, a 4.96% decrease from a year earlier, with the FY2025 full-year figure at $109.6 million, up 6.91% from the prior year.
• Total Debt slipped to $100.3 million in Q1 2026 per BTAI's latest filing, from $109.6 million in the prior quarter.
• Across five years, Total Debt topped out at $109.6 million in Q4 2025 and bottomed at $56000.0 in Q1 2022.
• The 5-year median for Total Debt is $100.6 million (2023), against an average of $93.2 million.
• Across the five-year window, Total Debt jumped 170332.14% in 2023 and retreated 4.96% in 2026, its largest moves.
• Year by year, Total Debt stood at $93.5 million in 2022, then grew by 7.62% to $100.6 million in 2023, then increased by 1.9% to $102.5 million in 2024, then rose by 6.91% to $109.6 million in 2025, then slipped by 8.49% to $100.3 million in 2026.
• Per Business Quant, the three latest BTAI Total Debt figures stand at $100.3 million (Q1 2026), $109.6 million (Q4 2025), and $109.1 million (Q3 2025).